What Has Been The Evolution of the Tumor Necrosis Factor Inhibitor Drugs Market in Recent Years?
The tumor necrosis factor inhibitor drugs market has seen considerable growth due to a variety of factors.
• The market size for drugs inhibiting tumor necrosis factor has observed a slight expansion in the recent past. The market size, which was $42.22 billion in 2024, is predicted to ascend to $42.9 billion in 2025, marking a compound annual growth rate (CAGR) of 1.6%. Factors contributing to the growth during the historic period include clinical effectiveness, approval from the FDA, a rise in disease prevalence, advancements through clinical trials and research, increased adoption and endorsements by physicians and heightened patient demand and satisfaction.
What Is the Forecasted Market Size and Growth Rate for The Tumor Necrosis Factor Inhibitor Drugs Market Size?
The Tumor Necrosis Factor Inhibitor Drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The market for drugs that inhibit tumor necrosis factor is predicted to experience stable expansion in the coming years. It is estimated to amplify to a size of $48.24 billion in 2029, experiencing a compound annual growth rate (CAGR) of 3.0%.
This anticipated growth over the forecast period can be traced back to progress in emerging markets, adaptations in regulations and approvals, individualized medical strategies, increase in healthcare education and access, and progress in biological therapies. The forecast period is likely to witness several key trends including patient-oriented solutions, practical evidence and data, emphasis on safety and side effects, groundbreaking drug delivery systems, and broadened clinical applications.
What Factors Are Driving Growth In The Tumor Necrosis Factor Inhibitor Drugs Market?
An upswing in autoimmune disease prevalence is presumed to propel the tumor necrosis factor inhibitor drugs market’s enhancement. Autoimmune disorders occur when the body's immune mechanism mistakenly attacks and exterminates healthy human tissue. The tumor necrosis factor inhibiting drug is administered in these disorders to mitigate inflammation if any discomfort, swelling or disease is present, by blocking the inflammatory process. This drug enhances the immune system, stabilizing it and defending the body from inflammation. For example, in June 2022, the Autoimmune Association, based in the US, reported that 4.7 million US males were afflicted with autoimmune diseases, accounting for 20% of all patients with autoimmune diseases. It was also reported in the same year that 31 million people in the US had 80-150 distinct autoimmune illnesses which is projected to rise in the future. Consequently, a surge in the occurrence of autoimmune diseases is stimulating the tumor necrosis factor inhibitor drugs market growth.
What Are The Main Segments Of The Global Tumor Necrosis Factor Inhibitor Drugs Market?
The tumor necrosis factor inhibitor drugs market covered in this report is segmented –
1) By Product Type: Humira, Enbrel, Remicade, Simponi Or Simponi Aria, Cimzia, Biosimilars
2) By Route Of Administration: Subcutaneous Injection, Intravenous Injection
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Other Applications
Subsegments:
1) By Humira: Humira (adalimumab)
2) By Enbrel: Enbrel (etanercept)
3) By Remicade: Remicade (infliximab)
4) By Simponi Or Simponi Aria: Simponi (golimumab), Simponi Aria
5) By Cimzia: Cimzia (certolizumab pegol)
6) By Biosimilars: Biosimilars Of Humira, Biosimilars Of Enbrel, Biosimilars Of Remicade, Biosimilars Of Simponi, Biosimilars Of Cimzia
Pre-Book The Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Tumor Necrosis Factor Inhibitor Drugs Market?
Advancements in product offerings have become a significant trend in propelling the tumor necrosis factor inhibitor drugs market's growth. The major players in this market are concentrating on innovation to solidify their market position. As an example, in May 2024, the American pharmaceutical corporation Teva Pharmaceuticals collaborated with the biotechnology firm Alvotech, based in Luxembourg. They announced the launch of SIMLANDI (adalimumab-ryvk) injection in the United States, a biosimilar to Humira that is interchangeable and used to treat several conditions including adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa, and adult uveitis.
Who Are the Key Players In The Tumor Necrosis Factor Inhibitor Drugs Market?
Major companies operating in the tumor necrosis factor inhibitor drugs market include:
• AbbVie Inc.
• Amgen Inc.
• Johnson & Johnson Services Inc.
• UCB S.A.
• Novartis International AG
• Pfizer Inc.
• Samsung Bioepis Co. Ltd.
• Sanofi SA
• Merck & Co. Inc.
• Boehringer Ingelheim Pharmaceuticals
• Lupin Ltd.
• F. Hoffmann-La Roche AG
• Cadila Healthcare Ltd.
• Aryogen Biopharma
• Casi Pharmaceuticals
• Celltrion Inc.
• Bristol-Myers Squibb
• Dexa Medica
• Epirus Biopharmaceuticals
• Glaxosmithkline plc
• Hanall Biopharma
• Intas Pharmaceuticals
• Leo Pharma AS
• Biogen Inc.
What Is The Most Dominant Region In The Tumor Necrosis Factor Inhibitor Drugs Market?
North America was the largest region in the tumor necrosis factor inhibitor drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the tumor necrosis factor (TNF) inhibitors drugs market report during the forecast period. The regions covered in the tumor necrosis factor inhibitor drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
